Tags

Type your tag names separated by a space and hit enter

[Cutaneous leishmaniasis in France: towards the end of injectable therapy?].
Bull Soc Pathol Exot. 2003 Jan; 96(5):383-8.BS

Abstract

Today no drug likely to be efficient on the majority of human-infecting species, well tolerated, and easy to administer is available for the treatment of human cutaneous leishmaniasis. But recent progress has been made. Efficient against visceral leishmaniasis, orally administered miltefosine may supplant pentavalent antimonials for the treatment of cutaneous leishmaniasis acquired in the New World. Right now, the reference treatment is still parenteral pentavalent antimonials 20 mg Sbv/kg/d for a duration that may probably be reduced from 20 to 10 days. The benefit/risk ratio of pentamidine still compares well with that of pentavalent antimonials for the treatment of lesions due to species belonging to the L. panamensis/L. guyanensis/L. shawi group. Pentamidine, which is easier to handle than antimonials, remains the reference treatment for cases from areas where these species predominate. Oral fluconazole is an improvement, readily available for cases from L. major foci. If its efficacy is confirmed in other foci and against other species, mechanisms will have to be implemented to make this therapeutic improvement affordable to poor patients in endemic countries. The development of an efficient and well tolerated topical treatment is still warranted. A new formulation of aminosidine is currently under evaluation. One can hope that the treatment of cutaneous leishmaniasis will soon become simpler, both for patients and doctors. For the benefits of this simplification to be rapidly affordable to all patients, the pharmaceutical and clinical research outlay must be maintained.

Authors+Show Affiliations

Centre médical de l'Institut Pasteur, 211 rue de Vaugirard, 75724 Paris Cedex 15, France. pabuffet@pasteur.frNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

15015844

Citation

Buffet, P A., and G Morizot. "[Cutaneous Leishmaniasis in France: Towards the End of Injectable Therapy?]." Bulletin De La Societe De Pathologie Exotique (1990), vol. 96, no. 5, 2003, pp. 383-8.
Buffet PA, Morizot G. [Cutaneous leishmaniasis in France: towards the end of injectable therapy?]. Bull Soc Pathol Exot. 2003;96(5):383-8.
Buffet, P. A., & Morizot, G. (2003). [Cutaneous leishmaniasis in France: towards the end of injectable therapy?]. Bulletin De La Societe De Pathologie Exotique (1990), 96(5), 383-8.
Buffet PA, Morizot G. [Cutaneous Leishmaniasis in France: Towards the End of Injectable Therapy?]. Bull Soc Pathol Exot. 2003;96(5):383-8. PubMed PMID: 15015844.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cutaneous leishmaniasis in France: towards the end of injectable therapy?]. AU - Buffet,P A, AU - Morizot,G, PY - 2004/3/16/pubmed PY - 2005/4/27/medline PY - 2004/3/16/entrez SP - 383 EP - 8 JF - Bulletin de la Societe de pathologie exotique (1990) JO - Bull Soc Pathol Exot VL - 96 IS - 5 N2 - Today no drug likely to be efficient on the majority of human-infecting species, well tolerated, and easy to administer is available for the treatment of human cutaneous leishmaniasis. But recent progress has been made. Efficient against visceral leishmaniasis, orally administered miltefosine may supplant pentavalent antimonials for the treatment of cutaneous leishmaniasis acquired in the New World. Right now, the reference treatment is still parenteral pentavalent antimonials 20 mg Sbv/kg/d for a duration that may probably be reduced from 20 to 10 days. The benefit/risk ratio of pentamidine still compares well with that of pentavalent antimonials for the treatment of lesions due to species belonging to the L. panamensis/L. guyanensis/L. shawi group. Pentamidine, which is easier to handle than antimonials, remains the reference treatment for cases from areas where these species predominate. Oral fluconazole is an improvement, readily available for cases from L. major foci. If its efficacy is confirmed in other foci and against other species, mechanisms will have to be implemented to make this therapeutic improvement affordable to poor patients in endemic countries. The development of an efficient and well tolerated topical treatment is still warranted. A new formulation of aminosidine is currently under evaluation. One can hope that the treatment of cutaneous leishmaniasis will soon become simpler, both for patients and doctors. For the benefits of this simplification to be rapidly affordable to all patients, the pharmaceutical and clinical research outlay must be maintained. SN - 0037-9085 UR - https://www.unboundmedicine.com/medline/citation/15015844/[Cutaneous_leishmaniasis_in_France:_towards_the_end_of_injectable_therapy]_ L2 - http://www.diseaseinfosearch.org/result/4166 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.